207 related articles for article (PubMed ID: 34029164)
1. Cohort Generation and Characterization of Patient-Specific Familial Hypercholesterolemia Induced Pluripotent Stem Cells.
Omer L; Hudson EA; Hudgins LC; Boyd NL
Stem Cells Dev; 2021 Jun; 30(12):632-640. PubMed ID: 34029164
[TBL] [Abstract][Full Text] [Related]
2. Function and Immunogenicity of Gene-corrected iPSC-derived Hepatocyte-Like Cells in Restoring Low Density Lipoprotein Uptake in Homozygous Familial Hypercholesterolemia.
Okada H; Nakanishi C; Yoshida S; Shimojima M; Yokawa J; Mori M; Tada H; Yoshimuta T; Hayashi K; Yamano T; Hanayama R; Yamagishi M; Kawashiri MA
Sci Rep; 2019 Mar; 9(1):4695. PubMed ID: 30886174
[TBL] [Abstract][Full Text] [Related]
3. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.
Sánchez-Hernández RM; Civeira F; Stef M; Perez-Calahorra S; Almagro F; Plana N; Novoa FJ; Sáenz-Aranzubía P; Mosquera D; Soler C; Fuentes FJ; Brito-Casillas Y; Real JT; Blanco-Vaca F; Ascaso JF; Pocovi M
Circ Cardiovasc Genet; 2016 Dec; 9(6):504-510. PubMed ID: 27784735
[TBL] [Abstract][Full Text] [Related]
4. Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study.
Raal FJ; Sjouke B; Hovingh GK; Isaac BF
Atherosclerosis; 2016 May; 248():238-44. PubMed ID: 27017151
[TBL] [Abstract][Full Text] [Related]
5. Induced pluripotent stem cell line ICGi037-A, obtained by reprogramming peripheral blood mononuclear cells from a patient with familial hypercholesterolemia due to heterozygous p.Trp443Arg mutations in LDLR.
Zakharova IS; Shevchenko AI; Tmoyan NA; Elisaphenko EA; Kalinin AP; Sleptcov AA; Nazarenko MS; Ezhov MV; Kukharchuk VV; Parfyonova YV; Zakian SM
Stem Cell Res; 2022 Apr; 60():102703. PubMed ID: 35152179
[TBL] [Abstract][Full Text] [Related]
6. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
[TBL] [Abstract][Full Text] [Related]
7. Induced pluripotent stem cell line ICGi038-A, obtained by reprogramming peripheral blood mononuclear cells from a patient with familial hypercholesterolemia due to compound heterozygous c.1246C > T/c.940 + 3_940 + 6del mutations in LDLR.
Zakharova IS; Shevchenko AI; Tmoyan NA; Elisaphenko EA; Zubkova ES; Sleptcov AA; Nazarenko MS; Ezhov MV; Kukharchuk VV; Parfyonova YV; Zakian SM
Stem Cell Res; 2022 Apr; 60():102702. PubMed ID: 35152178
[TBL] [Abstract][Full Text] [Related]
8. Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica.
Alves AC; Alonso R; Diaz-Diaz JL; Medeiros AM; Jannes CE; Merchan A; Vasques-Cardenas NA; Cuevas A; Chacra AP; Krieger JE; Arroyo R; Arrieta F; Schreier L; Corral P; Bañares VG; Araujo MB; Bustos P; Asenjo S; Stoll M; Dell'Oca N; Reyes M; Ressia A; Campo R; Magaña-Torres MT; Metha R; Aguilar-Salinas CA; Ceballos-Macias JJ; Morales ÁJR; Mata P; Bourbon M; Santos RD
Arterioscler Thromb Vasc Biol; 2020 Oct; 40(10):2508-2515. PubMed ID: 32757650
[TBL] [Abstract][Full Text] [Related]
9. Patient-Specific Induced Pluripotent Stem Cell-Derived Hepatocyte-Like Cells as a Model to Study Autosomal Recessive Hypercholesterolemia.
Nikasa P; Tricot T; Mahdieh N; Baharvand H; Totonchi M; Hejazi MS; Verfaillie CM
Stem Cells Dev; 2021 Jul; 30(14):714-724. PubMed ID: 33938231
[TBL] [Abstract][Full Text] [Related]
10. Three patients with homozygous familial hypercholesterolemia: Genomic sequencing and kindred analysis.
Wong KHY; Levy-Sakin M; Ma W; Gonzaludo N; Mak ACY; Vaka D; Poon A; Chu C; Lao R; Balamir M; Grenville Z; Wong N; Kane JP; Kwok PY; Malloy MJ; Pullinger CR
Mol Genet Genomic Med; 2019 Dec; 7(12):e1007. PubMed ID: 31617323
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia.
Vuorio A; Tikkanen MJ; Kovanen PT
Vasc Health Risk Manag; 2014; 10():263-70. PubMed ID: 24851052
[TBL] [Abstract][Full Text] [Related]
12. An integration-free iPSC line ZZUNEUi029-A derived from peripheral blood mononuclear cells of a patient with familial hypercholesterolemia carrying a mutation in LDLR gene.
Zhu K; Zhao J; Qin F; Chen X; Xu H; Li X; Tao H
Stem Cell Res; 2023 Sep; 71():103182. PubMed ID: 37586167
[TBL] [Abstract][Full Text] [Related]
13. Review of the scientific evolution of gene therapy for the treatment of homozygous familial hypercholesterolaemia: past, present and future perspectives.
Rodriguez-Calvo R; Masana L
J Med Genet; 2019 Nov; 56(11):711-717. PubMed ID: 30877235
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations.
Stein EA; Dann EJ; Wiegman A; Skovby F; Gaudet D; Sokal E; Charng MJ; Mohamed M; Luirink I; Raichlen JS; Sundén M; Carlsson SC; Raal FJ; Kastelein JJP
J Am Coll Cardiol; 2017 Aug; 70(9):1162-1170. PubMed ID: 28838366
[TBL] [Abstract][Full Text] [Related]
15. JD induced pluripotent stem cell-derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia.
Cayo MA; Cai J; DeLaForest A; Noto FK; Nagaoka M; Clark BS; Collery RF; Si-Tayeb K; Duncan SA
Hepatology; 2012 Dec; 56(6):2163-71. PubMed ID: 22653811
[TBL] [Abstract][Full Text] [Related]
16. The clinical and molecular diversity of homozygous familial hypercholesterolemia in children: Results from the GeneTics of clinical homozygous hypercholesterolemia (GoTCHA) study.
Luirink IK; Braamskamp MJAM; Wiegman A; Hartgers ML; Sjouke B; Defesche JC; Hovingh GK
J Clin Lipidol; 2019; 13(2):272-278. PubMed ID: 30795984
[TBL] [Abstract][Full Text] [Related]
17. Screening of LDLR and APOB gene mutations in Mexican patients with homozygous familial hypercholesterolemia.
Hernández Flores TJ; González García JR; Colima Fausto AG; Vázquez Cárdenas NA; Sánchez López Y; Zarate Morales CA; Magaña Torres MT
J Clin Lipidol; 2018; 12(3):693-701. PubMed ID: 29576406
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry.
Alonso R; Díaz-Díaz JL; Arrieta F; Fuentes-Jiménez F; de Andrés R; Saenz P; Ariceta G; Vidal-Pardo JI; Almagro F; Argueso R; Prieto-Matos P; Miramontes JP; Pintó X; Rodriguez-Urrego J; Perez de Isla L; Mata P
J Clin Lipidol; 2016; 10(4):953-961. PubMed ID: 27578128
[TBL] [Abstract][Full Text] [Related]
19. Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives.
Sanna C; Stéphenne X; Revencu N; Smets F; Sassolas A; Di Filippo M; Descamps OS; Sokal EM
Atherosclerosis; 2016 Apr; 247():97-104. PubMed ID: 26894473
[TBL] [Abstract][Full Text] [Related]
20. Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features.
Bertolini S; Calandra S; Arca M; Averna M; Catapano AL; Tarugi P;
Atherosclerosis; 2020 Nov; 312():72-78. PubMed ID: 32977124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
